Navigation Links
Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takeda's DEXILANT®
Date:3/2/2011

FREMONT, Calif., March 2, 2011 /PRNewswire/ -- Handa Pharmaceuticals, LLC ("Handa"), a specialty pharmaceutical company based in Fremont, California, today confirmed that its Abbreviated New Drug Application ("ANDA") for Dexlansoprazole Delayed Release Capsules, 60 mg, a generic version of Takeda's DEXILANT®, has been accepted for review by the U.S. Food and Drug Administration ("FDA"). Based upon available information, Handa believes that it is the first applicant to file an ANDA for DEXILANT® containing a Paragraph IV certification, under the provisions of the Hatch-Waxman Act. Should its ANDA for Dexlansoprazole Delayed Release Capsules, 60 mg, be approved by the FDA, Handa believes that the product may be entitled to 180 days of generic market exclusivity.

According to IMS Health, annual sales of DEXILANT® Delayed Release Capsules, 60 mg, in the U.S. were about $300 million for the twelve months ended December 31, 2010.

About Handa Pharmaceuticals, LLC Handa Pharmaceuticals, LLC is a specialty pharmaceutical company that was established in the San Francisco Bay area in November 2005. Handa's executive leadership has a proven track record of developing controlled-release prescription pharmaceutical products that are difficult to formulate. In December 2010, Handa announced that the U.S. Food and Drug Administration ("FDA") had granted tentative approval of the Company's Abbreviated New Drug Application ("ANDA") for Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg, a generic version of AstraZeneca's SEROQUEL XR®. Handa is the first applicant to file an ANDA for SEROQUEL XR® 50 mg, 150 mg, 200 mg, and 300 mg containing a Paragraph IV certification, under the provisions of the Hatch-Waxman Act. For more information, please visit http://www.handapharma.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Handa's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Handa disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Handa's current expectations depending upon a number of factors affecting Handa's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and demand for Handa's products; difficulties or delays in manufacturing; and other risks and uncertainties.

DEXILANT® is a registered trademark of Takeda Pharmaceuticals North America, Inc.

SEROQUEL® and SEROQUEL XR® are registered trademarks of the AstraZeneca group of companies.Company Contact: Stephen CaryExecutive Vice President and COO Handa Pharmaceuticals, LLC(510) 354-2888stephen.cary@handapharma.comhttp://www.handapharma.comThis press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>

SOURCE Handa Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
2. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
3. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
4. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
5. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
6. Access Pharmaceuticals to Host Update Conference Call for Investors
7. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
8. Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results Conference Call on March 7
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
11. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... Endo International plc (NASDAQ: ENDP ) will announce its ... its senior management team will host a conference call and webcast ... The dial-in number to access the call is U.S./ ... passcode is 45397076. Please dial in 10 minutes prior to the ... replay of the call will be available from August 8, 2017 ...
(Date:7/13/2017)...  New York City-based market research firm Kalorama Information notes ... of.  From new products to new costs, to the threat ... completed study, Potential Pipeline Disruptors . Among ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... impact the growing population and, to a more extreme extent, ...
(Date:7/11/2017)... N.J. , July 11, 2017  Bayer has awarded ... eight countries as part of its prestigious Bayer Hemophilia Awards ... Hospital of Philadelphia and Uniformed Services ... are among the winners. Grant recipients were announced last ... and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Cosmetic Town, an online plastic ... cosmetic surgeries they perform on a daily basis. , The new video series ... they specialize in at their practices. , When asked about the new video ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... California effectively destroyed the construction site and threatened numerous homes and businesses nearby, ... article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Every year, ... invigorating and educational conference, InstructureCon. Each annual event is coupled with a dynamic theme ... with a James Bond theme, Mission: InstructureCon 0017. , To extend their partnership ...
(Date:7/24/2017)... PHILADELPHIA (PRWEB) , ... July 24, 2017 , ... ... Health , two organizations that already work hand-in-hand on an Innovation Collaboration program, ... transform the access, quality, experience and cost of the care members and patients ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Anyone who uses ... a watermelon, nor would a pharmacist using that same scale to dispense medication. The ... health. , These illustrations show why it is important to have the right ...
Breaking Medicine News(10 mins):